everolimus — CareFirst (Caremark)
Relapsed or refractory classic Hodgkin lymphoma
Initial criteria
- Used as single-agent subsequent therapy
Reauthorization criteria
- Continuation may be approved when no unacceptable toxicity or disease progression
Approval duration
12 months